August 2025 Registered Direct Common Warrants
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
OCGN$0.7432+2.55%
Ocugen, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$252.03M
Float & O/S:
Inst Own:
DilutionScan read 44 of Ocugen, Inc.'s SEC filings and found 3 warrant series, 3 convertibles, 2 shelf registrations and 4 completed offerings on file for OCGN. The latest dilution event on file is an offering on May 14, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
OCGN
Going-concern warning, negative equity
Snapshot
Ocugen is a clinical-stage biotech with almost no product revenue ($4.4M in FY 2025) and a net loss of $67.8M, several times its revenue. It burned $57.1M in free cash flow last year and now shows negative stockholders' equity of -$16.6M.
What's Happening Right Now
- : Ocugen's Q2 2026 10-Q discloses going-concern doubt, negative stockholders' equity of -$16.6M, and a widened quarterly net loss of $24.9M despite holding $100.1M in cash after a $130M convertible notes deal.
- : Ocugen dosed the first patient in its Phase 3 trial of OCU410 for geographic atrophy, a program that holds FDA RMAT designation and targets a possible 2028 BLA filing.
- : Ocugen scheduled a September 21, 2026 special meeting asking shareholders to raise authorized shares from 390 million to 640 million, driven by covenants on its new convertible notes.
- : Ocugen posted a Q2 loss of $0.07 per share, missing the $0.05 estimate, with per-share losses wider than a year earlier even as revenue beat forecasts.
- : Ocugen signed a binding term sheet to license OCU400 in the Middle East and North Africa for up to $4M in near-term payments, up to $255M in sales milestones, and a 22% royalty.
Raise routes on file: effective shelf · latest dilution event 173 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
May 14, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Outstanding
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible Senior Notes due 2034
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series B Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Registered direct offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Registered direct offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your OCGN trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
